---
title: "Biocytogen Clarifies AGM Resolution on RMB1.5 Billion Credit Facilities and Guarantees"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285576023.md"
description: "Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has clarified a clerical error in its AGM circular regarding a special resolution for credit facilities. The company plans to seek a consolidated bank credit line of up to RMB1.5 billion and provide guarantees for its subsidiaries' loans. This move aims to enhance financial flexibility and risk management, concentrating credit exposure at the group level. The company focuses on drug research and development and operates through its parent and subsidiaries, utilizing bank credit for funding needs."
datetime: "2026-05-07T14:40:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285576023.md)
  - [en](https://longbridge.com/en/news/285576023.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285576023.md)
---

# Biocytogen Clarifies AGM Resolution on RMB1.5 Billion Credit Facilities and Guarantees

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has shared an update.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has issued a clarification regarding a clerical error in its recent AGM circular, correcting the wording of a special resolution on proposed comprehensive credit facilities and guarantees for the company and its subsidiaries. The company now confirms it plans to seek a consolidated bank credit line of up to RMB1.5 billion within a year of AGM approval, and to provide joint and several liability guarantees for loans of its wholly owned subsidiaries within the same overall limit, with all other information in the circular remaining unchanged.

The clarified resolution underscores Biocytogen’s intent to secure substantial financing capacity to support production, operations and project funding while centralizing risk management through parent-level guarantees for subsidiary borrowing. This move may enhance financial flexibility and bargaining power with lenders, but also concentrates credit exposure at the group level, a point of potential interest to shareholders and creditors evaluating the company’s capital structure and risk profile.

**More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H**

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a Hong Kong-listed biopharmaceutical company focused on drug research, development and related production and operations. The group operates through the parent company and wholly owned subsidiaries, using bank credit facilities and financing tools to support working capital and project funding needs.

**Average Trading Volume:** 1,355,077

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$20.14B

### Related Stocks

- [688796.CN](https://longbridge.com/en/quote/688796.CN.md)
- [02315.HK](https://longbridge.com/en/quote/02315.HK.md)

## Related News & Research

- [Biocytogen Publishes Audited 2025 Results and Sets Timeline for Full Annual Report](https://longbridge.com/en/news/280656260.md)
- [Biocytogen Forecasts Profit Surge on Overseas Expansion and Industry Recovery in 2025](https://longbridge.com/en/news/274121607.md)
- [20:00 ETLOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma](https://longbridge.com/en/news/286687690.md)
- [09:13 ETThe new Neurology-First Platform to Accelerate Clinical Trial Recruitment, Real-World Evidence, and Therapy Adoption](https://longbridge.com/en/news/286919710.md)
- [When Can We Expect A Profit From Island Pharmaceuticals Limited (ASX:ILA)?](https://longbridge.com/en/news/286861950.md)